MediciBIO Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
MediciBIO Co., Ltd. - overview
Established
2021
Location
Yongin, Gyeonggido, South Korea
Primary Industry
Biotechnology
About
Based in South Korea, MediciBIO Co. , Ltd. , operates as a developer of lipid nanoparticle platforms that deliver gene therapies and vaccines more effectively and safely. Based in Yongin, South Korea and founded in 2021, MediciBIO Co.
, Ltd. develops advanced therapeutic technologies for genetic disorders. The company raised KRW 4. 5 bn in Series A funding on September 22, 2026, from investors including Daedeok Venture Partners, ES Investor, and Kolon Investment.
The funding will enhance its gene delivery platform and support gene therapy development. MediciBIO specializes in advanced therapeutic technologies aimed at treating genetic disorders through innovative RNAi-based treatments. Their primary offerings include the Medici Targeting technology, which utilizes novel lipid compounds for targeted gene therapy delivery, and the Medici Lipid technology, producing lipid nanoparticles for efficient delivery systems in precision medicine. The company serves healthcare institutions, research organizations, and biotech firms across North America, Europe, and Asia.
MediciBIO generates revenue through strategic partnerships with biopharmaceutical firms and research institutions, leveraging its proprietary technology for drug development. Revenue streams include collaborative research agreements and licensing deals, with milestone payments tied to the development phases of licensed therapies. The company's core revenue-generating activities focus on its Medici Lipid nanoparticle technology and targeted gene therapies, primarily catering to B2B clients in the healthcare and pharmaceutical sectors. The company plans to enhance its gene delivery platform and support gene therapy development with the recent funding.
Current initiatives include expanding its capabilities in lipid nanoparticle technology to improve treatment efficacy for complex genetic diseases.
Current Investors
Kolon Investment, ES Investor, Daedeok Venture Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.medicibio.co.kr/
Company Stage
Series A
Total Amount Raised
Subscriber access only
MediciBIO Co., Ltd. - financials
| Fiscal Year Ended | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue (USD) | - | 120,000,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - |
| EBITDA (USD) | - | - | - | - | - |
| Operating Income (USD) | (102,000,000) | (1,069,000,000) | - | - | - |
| Operating Margin | - | (890.8%) | - | - | - |
| % EBITDA Margin | - | - | - | - | - |
| NET Income (USD) | (102,000,000) | (1,074,000,000) | - | - | - |
| % Net Margin | - | (895.0%) | - | - | - |
MediciBIO Co., Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A | Completed | MediciBIO Co., Ltd. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.